Key result
Thromboembolic events occurring at any time in patients with advanced gastroesophageal carcinoma were associated with significantly worse median overall survival (3.9 vs 8.7 months; P=0.007).
Why the study?
Does the occurrence of thromboembolic events reduce overall survival in patients with advanced gastroesophageal carcinoma undergoing chemotherapy?
Cohort (n=191)
Does the occurrence of thromboembolic events reduce overall survival in patients with advanced gastroesophageal carcinoma undergoing chemotherapy?
Absolute Event Rate: 3.9% vs 8.7%
p-value: p=0.007
The occurrence of thromboembolic events before or during chemotherapy is associated with significantly worse overall survival in patients with advanced gastroesophageal carcinoma.
No takes yet. Share an insight, caveat, or question.
Thromboembolic events signal poorer prognosis in advanced gastroesophageal cancer; leaves open whether anticoagulation improves survival.
Tetzlaff et al. (2007) conducted a cohort in Advanced gastroesophageal carcinoma (n=191). Thromboembolic events (TEEs) vs. No thromboembolic events was evaluated on Median overall survival (months) (p=0.007). Thromboembolic events occurring at any time in patients with advanced gastroesophageal carcinoma were associated with significantly worse median overall survival (3.9 vs 8.7 months; P=0.007).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: